

Sault Area Hospital January - December 2019 Antibiogram report

All Location Non-Urine Isolates – % Susceptible

Organism	# of isolates	All Location Non-Urine Isolates – % Susceptible																			
		Ampicillin	Amoxicillin-Clavulanic Acid	Penicillin	Cloxacillin	Piperacillin-Tazobactam	Ertapenem	Meropenem	Cefazolin	Ceftriaxone	Ceftazidime	Clindamycin	Erythromycin	Trimethoprim-Sulfamethoxazole	Ciprofloxacin*	Levofloxacin*	Gentamicin	Tobramycin	Amikacin	Doxycycline	Vancomycin
GRAM-NEGATIVE ORGANISMS																					
<i>Pseudomonas aeruginosa</i>	141					80		91		89				78	81	90	96	98			
<i>Escherichia coli</i>	93	52	79			86	100	100	82	89	93			79	73		89	91	100	77	
<i>Klebsiella pneumoniae</i>	26	0	96			96	100	100	86	96	96			96	83		100	100	100	95	
<i>Proteus mirabilis</i>	20	100	100			100	100	100	89	100	100			95	70		100	100	100	0	
<i>Enterobacter cloacae cplx</i>	12	0	0			0	100	100	0					85	85		93	85	100	93	
<i>Serratia marcescens</i>	10	0	0			0	100	100	0					100	50		100	100	100	33	
GRAM-POSITIVE ORGANISMS																					
<i>Staphylococcus aureus</i> , all isolates	543				66	66	66	66	66		77	50	100	82				97	100		
-methicillin-susceptible	359				100	100	100	100	100		83	71	100	88				97	100		
- methicillin-resistant (MRSA)	184				0	0	0	0	0		65	10	100	70				97	100	100	
Coagulase-negative staphylococci	192				51	51	51	51	51		62	39	70	71				86	100		
<i>Streptococcus agalactiae</i>	61			100							44	50							100		
<i>Group A streptococci</i>	50			100							64	59							100		
<i>Group G streptococci</i>	36			100							86	86							100		
<i>Group C streptococci</i>	15			100							83	83							100		
<i>Streptococcus pneumoniae</i>	40			100							90	79	90	100				90	100		
<i>Enterococcus faecalis</i>	28	100	100	100		100												100	100		

General Notes:

- Statistical validity of percent susceptibility for organisms for which there are fewer than 30 reported is limited. Please take this into consideration when interpreting the reported results.
- Some organisms for which there were only very small numbers have been excluded from this report
- Patient duplicates excluded
- Non-urine Isolates includes all specimen types other than urine and surveillance
- *Revised lower 2019 CLSI breakpoints for testing of Ciprofloxacin and Levofloxacin with Enterobacteriaceae and *P. aeruginosa* may result in lower % Susceptible rates. Please take this into consideration when interpreting the reported results

Sault Area Hospital January - December 2019 Antibiogram report

All Locations Urine Isolates – % Susceptible

Organism	# of isolates	All Locations Urine Isolates – % Susceptible																					
		Ampicillin	Amoxicillin-Clavulanic Acid	Penicillin	Cloxacillin	Piperacillin-Tazobactam	Ertapenem	Meropenem	Cephalexin	V Cefazolin	Ceftriaxone	Ceftazidime	Clindamycin	Erythromycin	Trimethoprim-Sulfamethoxazole	Ciprofloxacin*	Nitrofurantoin	Gentamicin	Tobramycin	Amikacin	Doxycycline	Vancomycin	Linezolid
GRAM-NEGATIVE ORGANISMS																							
Gram-Negative	<i>Escherichia coli</i>	914	63	82			93	100	100	93	87	95	96			84	81	96	93	94	100	84	
	<i>Klebsiella pneumoniae</i>	141	0	95			94	100	100	96	94	95	95			91	91	30	96	97	100	88	
	<i>Pseudomonas aeruginosa</i>	72					91		96				92				81		89	96	97		
	<i>Proteus mirabilis</i>	82	91	96			100	100	100	99	84	100	100			96	89	0	99	92	100	0	
	<i>Enterobacter species</i>	61	0	0			0	100	100		0					84	85	42	96	92	100	92	
	<i>Klebsiella oxytoca</i>	37	0	82			77	100	100		29	84	84			98	87	73	98	100	100	95	
	<i>Citrobacter species</i>	53	0	0			0	100	100							93	86	95	97	98	100	82	
	<i>Serratia marcescens</i>	18	0	0			0	100	100		0					100	100	0	100	94	100	33	
GRAM-POSITIVE ORGANISMS																							
Gram-Positive	<i>Enterococcus faecalis</i>	104	100	100	100		100										70	99			23	100	100
	<i>Staphylococcus aureus, all isolates</i>	27				85	85	85	85	85						97	66	97			100	100	
	-methicillin-susceptible	23				100	100	100	100	100	100	100				96	78	96			100	100	
	- methicillin-resistant (MRSA)	4				0	0	0	0	0	0	0				100	0	100			100	100	
	Coagulase-negative staphylococci	27				52	52	52	52	52						60	48	90			90	100	
	<i>Enterococcus faecium</i>	14	0	0	0		0										0	0			50	100	100

General Notes:

- Statistical validity of estimates of percent susceptibility for organisms for which there are fewer than 30 reported is limited. Please take this into consideration when interpreting the reported results.
- Some organisms for which there were only very small numbers have been excluded from this report
- Patient duplicates excluded
- *Revised lower 2019 CLSI breakpoints for testing of Ciprofloxacin and Levofloxacin with Enterobacteriaceae and *P. aeruginosa* may result in lower % Susceptible rates. Please take this into consideration when interpreting the reported results

Sault Area Hospital 2019 Antibiogram report

All Locations Blood Isolates – % Susceptible

Organism	# of isolates	All Locations Blood Isolates – % Susceptible																				
		Ampicillin	Amoxicillin-Clavulanic Acid	Penicillin	Cloxacillin	Piperacillin-Tazobactam	Ertapenem	Meropenem	Cefazolin	Ceftriaxone	Ceftazidime	Clindamycin	Erythromycin	Trimethoprim-Sulfamethoxazole	Ciprofloxacin*	-levofloxacin*	Gentamicin	Tobramycin	Amikacin	Doxycycline	Vancomycin	Linezolid
Gram-Negative	GRAM-NEGATIVE ORGANISMS																					
	<i>Escherichia coli</i>	67	55	81			89	100	100	86	90	94			78	73		84	89	100	79	
	<i>Klebsiella pneumoniae</i>	19	0	100			100	100	100	95	100	100			100	85		100	100	100	94	
Gram-Positive	GRAM-POSITIVE ORGANISMS																					
	<i>Coagulase-negative staphylococci</i>	162				51	51	51	51	51			63	38	70	69				84	100	
	<i>Staphylococcus aureus, all isolates</i>	56				75	75	75	75	75			71	55	100	71				100	100	
	-methicillin-susceptible	42				100	100	100	100	100			76	69	100	95				100	100	
	- methicillin-resistant (MRSA)	14				0	0	0	0	0			57	14	100	0				100	100	100
	<i>Enterococcus faecalis</i>	16	100	100	100		100													100	100	
	<i>Group B streptococci</i>	14	100	100	100		100						46	46						100		
	<i>Group G streptococci</i>	12	100	100	100		100						92	92						100		
	<i>Streptococcus pneumoniae</i>	11			100								82	65	91		100			82	100	

- Statistical validity of estimates of percent susceptibility for organisms for which there are fewer than 30 reported is limited.
- Some organisms for which there were only very small numbers have been excluded from this
- Patient duplicates excluded
- *Revised lower 2019 CLSI breakpoints for testing of Ciprofloxacin and Levofloxacin with Enterobacteriaceae and *P. aeruginosa* may result in lower % Susceptible rates. Please take this into consideration when interpreting the reported results

Prepared by Marianne Cuglietta, Senior Technologist Microbiology

Jun-20

Sault Area Hospital January - December 2019 Antibiogram report

In-Patient Non-Urine Isolates – % Susceptible

Organism	# of isolates	% Susceptible																			
		Ampicillin	Amoxicillin-Clavulanic Acid	Penicillin	Cloxacillin	Piperacillin-Tazobactam	Ertapenem	Meropenem	Cefazolin	Ceftriaxone	Ceftazidime	Clindamycin	Erythromycin	Trimethoprim-Sulfamethoxazole	Ciprofloxacin*	Levofloxacin*	Gentamicin	Tobramycin	Amikacin	Doxycycline	Vancomycin
GRAM-NEGATIVE ORGANISMS																					
<i>Pseudomonas aeruginosa</i>	54					81		92		87					80	74	90	94	99		
<i>Escherichia coli</i>	21	63	79			85	100	100	79	85	90				68	87	95	90	100	74	
GRAM-POSITIVE ORGANISMS																					
<i>Staphylococcus aureus, all isolates</i>	99				65	65	65	65	65			63	44	100	60				98	100	100
-methicillin-susceptible	64				100	100	100	100	100			73	63	100	88				98	100	
- methicillin-resistant (MRSA)	35				0	0	0	0	0			46	8	100	9				98	100	100
Coagulase-negative staphylococci	36				45	45	45	45	45			64	34	76	76				82	100	
Group B streptococci	15			100								60	60							100	

General Notes:

- Statistical validity of estimates of percent susceptibility for organisms for which there are fewer than 30 isolates reported is limited. Please take this into consideration when interpreting the reported results.
- Some organisms for which there were only very small numbers have been excluded from this report
- Patient duplicates excluded
- Non-urine Isolates includes all specimen types other than urine and surveillance
- *Revised lower 2019 CLSI breakpoints for testing of Ciprofloxacin and Levofloxacin with Enterobacteriaceae and *P. aeruginosa* may result in lower % Susceptible rates. Please take this into consideration when interpreting the reported results

Prepared by Marianne Cuglietta, Senior Technologist Microbiology

Jun-20

Sault Area Hospital January - December 2019 Antibiogram report

In-Patient Urine Isolates – % Susceptible

Organism	# of isolates	In-Patient Urine Isolates – % Susceptible																					
		Ampicillin	Amoxicillin-Clavulanic Acid	Penicillin	Cloxacillin	Piperacillin-Tazobactam	Ertapenem	Meropenem	Cephalexin	IV Cefazolin	Ceftriaxone	Ceftazidime	Clindamycin	Erythromycin	Trimethoprim-Sulfamethoxazole	Ciprofloxacin*	Nitrofurantoin	Gentamicin	Tobramycin	Amikacin	Doxycycline	Vancomycin	Linezolid
GRAM-NEGATIVE ORGANISMS																							
Gram-Negative	<i>Escherichia coli</i>	123	56	76			89	100	100	89	79	96	96		83	77	93	92	92	100	82		
	<i>Klebsiella pneumoniae</i>	34	0	92			92	100	100	94	92	92	92		92	100	44	94	94	100	94		
	<i>Pseudomonas aeruginosa</i>	33					89		100				88				83		91	97	97		
	<i>Proteus mirabilis</i>	13	100	100			100	100	100	100	83	100	100		100	75	0	92	100	100	0		
	<i>Citrobacter species</i>	15	0	0			0	100	100		0				80	87	100	100	100	100	87		
	<i>Enterobacter species</i>	14	0	0			0	100	100		0				100	78	38	100	93	100	100		
	<i>Klebsiella oxytoca</i>	13	0	84			66	100	100		18	84			100	64	84	100	100	100	100		
GRAM-POSITIVE ORGANISMS																							
Gram-Positive	<i>Enterococcus faecalis</i>	49	100	100	100		100									71	100				21	100	100
	Coagulase-negative staphylococci	11				46	46	46	46		46				36	36	100				82	100	

General Notes:

- Statistical validity of estimates of percent susceptibility for organisms for which there are fewer than 30 isolates reported is limited. Please take this into consideration when interpreting the reported results.
- Some organisms for which there were only very small numbers have been excluded from this report
- Patient duplicates excluded
- *Revised lower 2019 CLSI breakpoints for testing of Ciprofloxacin and Levofloxacin with Enterobacteriaceae and *P. aeruginosa* may result in lower % Susceptible rates. Please take this into consideration when interpreting the reported results

Prepared by Marianne Cuglietta, Senior Technologist Microbiology

Jun-20

Sault Area Hospital January - December 2019 Antibiogram report

ED Non-Urine Isolates – % Susceptible

Organism	# of isolates	ED Non-Urine Isolates – % Susceptible																			
		Ampicillin	Ampicillin-Clavulanic Acid	Penicillin	Cloxacillin	Piperacillin-Tazobactam	Ertapenem	Meropenem	Cefazolin	Ceftriaxone	Ceftazidime	Clindamycin	Erythromycin	Trimethoprim-Sulfamethoxazole	Ciprofloxacin*	Levofloxacin*	Gentamicin	Tobramycin	Amikacin	Doxycycline	Vancomycin
GRAM-NEGATIVE ORGANISMS																					
<i>Escherichia coli</i>	53	51	81			89	100	100	85	94	96			78	76		85	88	100	80	
<i>Pseudomonas aeruginosa</i>	48					86		93			96				80	75	88	97	100		
<i>Klebsiella pneumoniae</i>	14	0	94			94	100	100	82	94	94			94	73		100	100	100	93	
GRAM-POSITIVE ORGANISMS																					
<i>Staphylococcus aureus</i> , all isolates	281			61	61	61	61	61				80	47	99	58				96	100	
-methicillin-susceptible	172			100	100	100	100	100				85	71	98	90				96	100	
- methicillin-resistant (<i>MRSA</i>)	109			0	0	0	0	0				71	9	100	8				96	100	100
Coagulase-negative staphylococci	80			60	60	60	60	60				63	38	72	77				84	100	
Group A streptococci	38		100									66	63							100	
<i>Streptococcus pneumoniae</i>	17		100									88	83	94		100			89	100	
Group G streptococci	24		100									92	88							100	
Group B streptococci	31		100									38	48							100	

General Notes:

- Statistical validity of estimates of percent susceptibility for organisms for which there are fewer than 30 isolates reported is limited. Please take this into consideration when interpreting the reported results.
- Some organisms for which there were only very small numbers have been excluded from this report
- Patient duplicates excluded
- Non-urine Isolates includes all specimen types other than urine and surveillance
- *Revised lower 2019 CLSI breakpoints for testing of Ciprofloxacin and Levofloxacin with Enterobacteriaceae and *P. aeruginosa* may result in lower % Susceptible rates. Please take this into consideration when interpreting the reported results

Sault Area Hospital January - December 2019 Antibiogram report

ED Urine Isolates – % Susceptible

Organism	# of isolates	ED Urine Isolates – % Susceptible																				
		Ampicillin	Amoxicillin-Clavulanic Acid	Penicillin	Cloxacillin	Piperacillin-Tazobactam	Ertapenem	Meropenem	Cephalexin	V Cefazolin	Ceftriaxone	Ceftazidime	Clindamycin	Erythromycin	Trimethoprim-Sulfamethoxazole	Ciprofloxacin*	Nitrofurantoin	Gentamicin	Tobramycin	Amikacin	Doxycycline	Vancomycin
GRAM-NEGATIVE ORGANISMS																						
Gram-Negative	<i>Escherichia coli</i>	544	65	86		93	100	100	95	89	96	96			83	83	96	93	94	100	85	
	<i>Klebsiella pneumoniae</i>	75	0	96		94	100	100	98	94	98	98			92	87	27	98	98	100	88	
	<i>Citrobacter species</i>	22	0	0		0	100	100		0					97	82	91	100	100	100	99	
	<i>Pseudomonas aeruginosa</i>	22				100		87				100				87		96	100	100		
	<i>Proteus mirabilis</i>	37	97	100		100	100	100	90	100	100				97	98	0	100	98	100	0	
	<i>Enterobacter species</i>	22	0	0		0	100	100		0					89	89	59	89	89	100	100	
	<i>Klebsiella oxytoca</i>	13	0	77		77	100	100		30	77				93	100	77	100	100	100	92	
Gram-Positive	GRAM-POSITIVE ORGANISMS																					
	<i>Enterococcus faecalis</i>	31	100	100	100	100										66	97			26	100	100

General Notes:

- Statistical validity of estimates of percent susceptibility for organisms for which there are fewer than 30 isolates reported is limited. Please take this into consideration when interpreting the reported results.
- Some organisms for which there were only very small numbers have been excluded from this report
- Patient duplicates excluded
- *Revised lower 2019 CLSI breakpoints for testing of Ciprofloxacin and Levofloxacin with Enterobacteriaceae and *P. aeruginosa* may result in lower % Susceptible rates. Please take this into consideration when interpreting the reported results

Prepared by Marianne Cuglietta, Senior Technologist Microbiology

Jun-20

Sault Area Hospital 2019 Antibiogram report

**2018-2019 ICU Non-Urine Isolates – % Susceptible

organism	# of isolates	% Susceptible																				
		Ampicillin	Amoxicillin-Clavulanic Acid	Penicillin	Cloxacillin	Piperacillin-Tazobactam	Ertapenem	Meropenem	Cefazolin	Ceftriaxone	Ceftazidime	Clindamycin	Erythromycin	Trimethoprim-Sulfamethoxazole	Ciprofloxacin*	Levofloxacin*	Gentamicin	Tobramycin	Amikacin	Doxycycline	Vancomycin	Lincosolid
																						
<i>Pseudomonas aeruginosa</i>	34					65		71			77				82	75	79	85	100			
<i>E. coli</i>	15	64	86			93	100	100	86	93	93			93	86		100	93	100	86		
GRAM-NEGATIVE ORGANISMS																						
<i>Staphylococcus aureus, all isolates</i>	60				78	78	78	78	78			75	61	100	69				100	100		
-methicillin-susceptible	47				100	100	100	100	100			83	74	100	88				100	100		
- methicillin-resistant (MRSA)	13				0	0	0	0	0			46	15	100	0				100	100	100	
<i>Coagulase-negative staphylococci</i>	52				35	35	35	35	35			48	29	59	55				93	100		
<i>Streptococcus pneumoniae</i>	16			100								93	69	94		100				94	100	
GRAM-POSITIVE ORGANISMS																						
<i>Staphylococcus aureus, all isolates</i>	60				78	78	78	78	78			75	61	100	69				100	100		
-methicillin-susceptible	47				100	100	100	100	100			83	74	100	88				100	100		
- methicillin-resistant (MRSA)	13				0	0	0	0	0			46	15	100	0				100	100	100	
<i>Coagulase-negative staphylococci</i>	52				35	35	35	35	35			48	29	59	55				93	100		
<i>Streptococcus pneumoniae</i>	16			100								93	69	94		100				94	100	

General Notes:

- Statistical validity of estimates of percent susceptibility for organisms for which there are fewer than 30 reported is limited. Please take this into consideration when interpreting the reported results.
- Some organisms for which there were only very small numbers have been excluded from this report
- Patient duplicates excluded
- Non-urine Isolates includes all specimen types other than urine and surveillance
- *Revised lower 2019 CLSI breakpoints for testing of Ciprofloxacin and Levofloxacin with Enterobacteriaceae and *P. aeruginosa* may result in lower % Susceptible rates. Please take this into consideration when interpreting the reported results

Prepared by Marianne Cuglietta, Senior Technologist Microbiology

Jun-20

Sault Area Hospital January - December 2019 Antibiogram report

Blood Isolates ALL Patients – % Susceptible

Organism	# of isolates	Fluconazole	Voriconazole	Caspofungin	Micafungin	Anidulafungin
ALL Candida	12					
<i>Candida albicans</i>	8	100	100	100	100	100
<i>Candida tropicalis</i>	2	100	50	100	100	100
<i>Candida dubliniensis</i>	1	100	100	100	100	100
<i>Candida glabrata</i> *	1	100		100	100	100

General Notes:

- Statistical validity of estimates of percent susceptibility for organisms for which there are fewer than 30 isolates reported is limited. Please take this into consideration when interpreting the reported results.
- Patient duplicates excluded
- **Candida glabrata* - There are no interpretative breakpoints for voriconazole. There are no susceptibility breakpoints for fluconazole, the percentage provided refers to the percentage of *Candida glabrata* that are susceptible dose-dependent.

Prepared by Marianne Cuglietta, Senior Technologist Microbiology

Jun-20